ArticleJournal of nanobiotechnology2025
Manganese ion chelated nanoassemblies synergizing metalloimmunotherapy - chemodynamic for potentiating glioblastoma treatment.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Glioblastoma (GBM) remains among the most aggressive brain malignancies, necessitating the development of novel therapeutic strategies. In this study, we designed a multifunctional magnetic-targeting nanoassembly (MnBPDF) by chelating Mn²⁺ with a dopamine-modified albumin coat, encapsulating a magnetic core constructed with magnetic Fe₃O₄ and doxorubicin. MnBPDF effectively induces oxidative stress and triggers immunogenic cell death (ICD), thereby releasing damage-associated molecular patterns that prime antigen-presenting cells (APCs) and subsequently activate tumor-specific cytotoxic T lymphocyte (CTL) responses. Moreover, Mn²⁺ simultaneously enhances the activation of cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway, triggering robust type I interferon production and amplifying antitumor immune responses. By boosting antigen presentation by dendritic cells (DCs) in the GBM microenvironment, this system promotes CTL infiltration and inhibits tumor progression. The synergistic effects of magnetic targeting, ICD induction, and enhanced immune activation highlight MnBPDF as a highly effective therapeutic strategy for GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.